{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:06:19Z","timestamp":1794265579460,"version":"4.9.0"},"reference-count":170,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["DGE-1644868"],"award-info":[{"award-number":["DGE-1644868"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["DGE-1644868"],"award-info":[{"award-number":["DGE-1644868"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R01AI145016"],"award-info":[{"award-number":["1R01AI145016"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R01AI145016"],"award-info":[{"award-number":["1R01AI145016"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Also Duke University"},{"DOI":"10.13039\/100000070","name":"U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["2R01EB009701"],"award-info":[{"award-number":["2R01EB009701"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Also funded by Duke University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Nanotechnol."],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1038\/s41565-020-0739-9","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T16:04:56Z","timestamp":1597680296000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":222,"title":["Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health"],"prefix":"10.1038","volume":"16","author":[{"given":"Chelsea N.","family":"Fries","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4452-0457","authenticated-orcid":false,"given":"Elizabeth J.","family":"Curvino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7646-4907","authenticated-orcid":false,"given":"Jui-Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1438-4554","authenticated-orcid":false,"given":"Sallie R.","family":"Permar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0960-1019","authenticated-orcid":false,"given":"Genevieve G.","family":"Fouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3536-4827","authenticated-orcid":false,"given":"Joel H.","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"key":"739_CR1","unstructured":"The top 10 causes of death. WHO https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death (2018)."},{"key":"739_CR2","unstructured":"Global Tuberculosis Report. WHO https:\/\/www.who.int\/tb\/publications\/global_report\/en\/ (2018)."},{"key":"739_CR3","unstructured":"World Malaria Report (WHO, 2018); https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/275867\/9789241565653-eng.pdf"},{"key":"739_CR4","unstructured":"Global HIV & AIDS statistics \u2014 2018 fact sheet. UNAIDS http:\/\/www.unaids.org\/en\/resources\/fact-sheet (2018)."},{"key":"739_CR5","doi-asserted-by":"crossref","first-page":"1801419","DOI":"10.1002\/adhm.201801419","volume":"18","author":"JM Gammon","year":"2019","unstructured":"Gammon, J. M. & Jewell, C. M. Engineering immune tolerance with biomaterials. Adv. Healthc. Mater. 18, 1801419\u201319 (2019).","journal-title":"Adv. Healthc. Mater."},{"key":"739_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.02224","volume":"9","author":"R Pati","year":"2018","unstructured":"Pati, R., Shevtsov, M. & Sonawane, A. Nanoparticle vaccines against infectious diseases. Front. Immunol. 9, 1\u201316 (2018).","journal-title":"Front. Immunol."},{"key":"739_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2019.02.012","volume":"88","author":"J Kim","year":"2019","unstructured":"Kim, J., Manspeaker, M. P. & Thomas, S. N. Augmenting the synergies of chemotherapy and immunotherapy through drug delivery. Acta Biomaterialia 88, 1\u201314 (2019).","journal-title":"Acta Biomaterialia"},{"key":"739_CR8","doi-asserted-by":"crossref","first-page":"11109","DOI":"10.1021\/acs.chemrev.5b00109","volume":"115","author":"DJ Irvine","year":"2015","unstructured":"Irvine, D. J., Hanson, M. C., Rakhra, K. & Tokatlian, T. Synthetic nanoparticles for vaccines and immunotherapy. Chem. Rev. 115, 11109\u201311146 (2015).","journal-title":"Chem. Rev."},{"key":"739_CR9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev-bioeng-071516-044603","volume":"19","author":"EA Scott","year":"2017","unstructured":"Scott, E. A., Karabin, N. B. & Augsornworawat, P. Overcoming immune dysregulation with immunoengineered nanobiomaterials. Annu. Rev. Biomed. Eng. 19, 57\u201384 (2017).","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"739_CR10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.addr.2017.03.005","volume":"114","author":"LH Tostanoski","year":"2017","unstructured":"Tostanoski, L. H. & Jewell, C. M. Engineering self-assembled materials to study and direct immune function. Adv. Drug Deliv. Rev. 114, 60\u201378 (2017).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"739_CR11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2017.04.009","volume":"114","author":"SH Kelly","year":"2017","unstructured":"Kelly, S. H., Shores, L. S., Votaw, N. L. & Collier, J. H. Biomaterial strategies for generating therapeutic immune responses. Adv. Drug Deliv. Rev. 114, 3\u201318 (2017).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"739_CR12","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1128\/jvi.68.7.4650-4655.1994","volume":"68","author":"RA Koup","year":"1994","unstructured":"Koup, R. A. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650\u20134655 (1994).","journal-title":"J. Virol."},{"key":"739_CR13","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1182\/blood-2005-12-4818","volume":"107","author":"MR Betts","year":"2006","unstructured":"Betts, M. R. et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107, 4781\u20134789 (2006).","journal-title":"Blood"},{"key":"739_CR14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QAD.0000000000000106","volume":"28","author":"P Hraber","year":"2014","unstructured":"Hraber, P. et al. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28, 163\u2013169 (2014).","journal-title":"AIDS"},{"key":"739_CR15","doi-asserted-by":"crossref","DOI":"10.1186\/s12977-018-0435-0","volume":"15","author":"J Finney","year":"2018","unstructured":"Finney, J. & Kelsoe, G. Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design. Retrovirology 15, 53 (2018).","journal-title":"Retrovirology"},{"key":"739_CR16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/imr.12075","volume":"254","author":"JR Mascola","year":"2013","unstructured":"Mascola, J. R. & Haynes, B. F. HIV-1 neutralizing antibodies: understanding nature\u2019s pathways. Immunological Rev. 254, 225\u2013244 (2013).","journal-title":"Immunological Rev."},{"key":"739_CR17","doi-asserted-by":"crossref","first-page":"e1000433","DOI":"10.1371\/journal.ppat.1000433","volume":"5","author":"AJ Hessell","year":"2009","unstructured":"Hessell, A. J. et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5, e1000433 (2009).","journal-title":"PLoS Pathog."},{"key":"739_CR18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/72318","volume":"6","author":"JR Mascola","year":"2000","unstructured":"Mascola, J. R. et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1\/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6, 207\u2013210 (2000).","journal-title":"Nat. Med."},{"key":"739_CR19","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1126\/science.1245625","volume":"342","author":"JP Julien","year":"2013","unstructured":"Julien, J. P. et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342, 1477\u20131483 (2013).","journal-title":"Science"},{"key":"739_CR20","doi-asserted-by":"crossref","first-page":"aab1253","DOI":"10.1126\/science.aab1253","volume":"349","author":"WB Williams","year":"2015","unstructured":"Williams, W. B. et al. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science 349, aab1253 (2015).","journal-title":"Science"},{"key":"739_CR21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/imr.12508","volume":"275","author":"G Kelsoe","year":"2017","unstructured":"Kelsoe, G. & Haynes, B. F. Host controls of HIV broadly neutralizing antibody development. Immunol. Rev. 275, 79\u201388 (2017).","journal-title":"Immunol. Rev."},{"key":"739_CR22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/imr.12504","volume":"275","author":"P Borrow","year":"2017","unstructured":"Borrow, P. & Moody, M. A. Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies. Immunol. Rev. 275, 62\u201378 (2017).","journal-title":"Immunol. Rev."},{"key":"739_CR23","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","volume":"361","author":"S Rerks-Ngarm","year":"2009","unstructured":"Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209\u20132220 (2009).","journal-title":"N. Engl. J. Med."},{"key":"739_CR24","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","volume":"366","author":"BF Haynes","year":"2012","unstructured":"Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275\u20131286 (2012).","journal-title":"N. Engl. J. Med."},{"key":"739_CR25","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.1073\/pnas.1301456110","volume":"110","author":"GD Tomaras","year":"2013","unstructured":"Tomaras, G. D. et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc. Natl Acad. Sci. USA 110, 9019\u20139024 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"739_CR26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/infdis\/jis367","volume":"206","author":"DC Montefiori","year":"2012","unstructured":"Montefiori, D. C. et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect. Dis. 206, 431\u2013441 (2012).","journal-title":"J. Infect. Dis."},{"key":"739_CR27","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1128\/JVI.01023-12","volume":"86","author":"M Bonsignori","year":"2012","unstructured":"Bonsignori, M. et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 86, 11521\u201311532 (2012).","journal-title":"J. Virol."},{"key":"739_CR28","doi-asserted-by":"crossref","first-page":"e0180720","DOI":"10.1371\/journal.pone.0180720","volume":"12","author":"LG Perez","year":"2017","unstructured":"Perez, L. G. et al. V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. PLoS ONE 12, e0180720 (2017).","journal-title":"PLoS ONE"},{"key":"739_CR29","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1126\/science.367.6478.611","volume":"367","author":"J Cohen","year":"2020","unstructured":"Cohen, J. Combo of two HIV vaccines fails its big test. Science 367, 611\u2013612 (2020).","journal-title":"Science"},{"key":"739_CR30","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1126\/science.aab3886","volume":"349","author":"DH Barouch","year":"2015","unstructured":"Barouch, D. H. et al. Protective efficacy of adenovirus\/protein vaccines against SIV challenges in rhesus monkeys. Science 349, 320\u2013324 (2015).","journal-title":"Science"},{"key":"739_CR31","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15711","volume":"8","author":"T Bradley","year":"2017","unstructured":"Bradley, T. et al. Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. Nat. Commun. 8, 15711 (2017).","journal-title":"Nat. Commun."},{"key":"739_CR32","doi-asserted-by":"crossref","first-page":"11181","DOI":"10.1073\/pnas.1103012108","volume":"108","author":"DR Burton","year":"2011","unstructured":"Burton, D. R. et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc. Natl Acad. Sci. USA 108, 11181\u201311186 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"739_CR33","doi-asserted-by":"crossref","first-page":"e1005042","DOI":"10.1371\/journal.ppat.1005042","volume":"11","author":"S Santra","year":"2015","unstructured":"Santra, S. et al. Human Non-neutralizing HIV-1 envelope monoclonal antibodies limit the number of founder viruses during SHIV mucosal infection in rhesus macaques. PLoS Pathog. 11, e1005042 (2015).","journal-title":"PLoS Pathog."},{"key":"739_CR34","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1128\/JVI.80.5.2515-2528.2006","volume":"80","author":"PL Moore","year":"2006","unstructured":"Moore, P. L. et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J. Virol. 80, 2515\u20132528 (2006).","journal-title":"J. Virol."},{"key":"739_CR35","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1128\/JVI.00154-11","volume":"85","author":"ET Crooks","year":"2011","unstructured":"Crooks, E. T., Tong, T., Osawa, K. & Binley, J. M. Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected. J. Virol. 85, 5825\u20135839 (2011).","journal-title":"J. Virol."},{"key":"739_CR36","doi-asserted-by":"crossref","first-page":"e1003618","DOI":"10.1371\/journal.ppat.1003618","volume":"9","author":"RW Sanders","year":"2013","unstructured":"Sanders, R. W. et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9, e1003618 (2013).","journal-title":"PLoS Pathog."},{"key":"739_CR37","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.1234150","volume":"340","author":"J Jardine","year":"2013","unstructured":"Jardine, J. et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 340, 711\u2013716 (2013).","journal-title":"Science"},{"key":"739_CR38","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1371\/journal.ppat.0030157","volume":"3","author":"M Rolland","year":"2007","unstructured":"Rolland, M., Nickle, D. C. & Mullins, J. I. HIV-1 group M conserved elements vaccine. PLoS Pathog. 3, e157 (2007).","journal-title":"PLoS Pathog."},{"key":"739_CR39","doi-asserted-by":"crossref","first-page":"8300","DOI":"10.1128\/JVI.00114-09","volume":"83","author":"BT Korber","year":"2009","unstructured":"Korber, B. T., Letvin, N. L. & Haynes, B. F. T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J. Virol. 83, 8300\u20138314 (2009).","journal-title":"J. Virol."},{"key":"739_CR40","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/infdis\/jis696","volume":"207","author":"C Sundling","year":"2013","unstructured":"Sundling, C. et al. Immunization of macaques with soluble HIV type 1 and influenza virus envelope glycoproteins results in a similarly rapid contraction of peripheral B-cell responses after boosting. J. Infect. Dis. 207, 426\u2013431 (2013).","journal-title":"J. Infect. Dis."},{"key":"739_CR41","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.3389\/fimmu.2018.02748","volume":"9","author":"LS Itsara","year":"2018","unstructured":"Itsara, L. S. et al. The Development of Whole Sporozoite Vaccines for Plasmodium falciparum Malaria. Front. Immunol. 9, 2748 (2018).","journal-title":"Front. Immunol."},{"key":"739_CR42","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/cid\/ciu954","volume":"60","author":"A Ouattara","year":"2015","unstructured":"Ouattara, A. & Laurens, M. B. Vaccines against malaria. Clin. Infect. Dis. 60, 930\u2013936 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"739_CR43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"SCTP Rts","year":"2015","unstructured":"Rts, S. C. T. P. Efficacy and safety of RTS, S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31\u201345 (2015).","journal-title":"Lancet"},{"key":"739_CR44","doi-asserted-by":"crossref","first-page":"e1001685","DOI":"10.1371\/journal.pmed.1001685","volume":"11","author":"SCTP Rts","year":"2014","unstructured":"Rts, S. C. T. P. Efficacy and safety of the RTS, S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLos Med. 11, e1001685 (2014).","journal-title":"PLos Med."},{"key":"739_CR45","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1016\/j.vaccine.2015.09.110","volume":"33","author":"A Ouattara","year":"2015","unstructured":"Ouattara, A. et al. Designing malaria vaccines to circumvent antigen variability. Vaccine 33, 7506\u20137512 (2015).","journal-title":"Vaccine"},{"key":"739_CR46","doi-asserted-by":"crossref","first-page":"e1003840","DOI":"10.1371\/journal.ppat.1003840","volume":"9","author":"S Dutta","year":"2013","unstructured":"Dutta, S. et al. Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1. PLoS Pathog. 9, e1003840 (2013).","journal-title":"PLoS Pathog."},{"key":"739_CR47","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1073\/pnas.1621489114","volume":"114","author":"D Kazmin","year":"2017","unstructured":"Kazmin, D. et al. Systems analysis of protective immune responses to RTS, S malaria vaccination in humans. Proc. Natl Acad. Sci. USA 114, 2425\u20132430 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"739_CR48","doi-asserted-by":"crossref","first-page":"14017","DOI":"10.1073\/pnas.0805452105","volume":"105","author":"NW Schmidt","year":"2008","unstructured":"Schmidt, N. W. et al. Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proc. Natl Acad. Sci. USA 105, 14017\u201314022 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"739_CR49","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1574-6976.2012.00331.x","volume":"36","author":"M Gengenbacher","year":"2012","unstructured":"Gengenbacher, M. & Kaufmann, S. H. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol. Rev. 36, 514\u2013532 (2012).","journal-title":"FEMS Microbiol. Rev."},{"key":"739_CR50","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.tube.2010.06.002","volume":"90","author":"IM Orme","year":"2010","unstructured":"Orme, I. M. The Achilles heel of BCG. Tuberculosis 90, 329\u2013332 (2010).","journal-title":"Tuberculosis"},{"key":"739_CR51","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3389\/fimmu.2017.01134","volume":"8","author":"HM Dockrell","year":"2017","unstructured":"Dockrell, H. M. & Smith, S. G. What have we learnt about BCG vaccination in the last 20 years? Front. Immunol. 8, 1134 (2017).","journal-title":"Front. Immunol."},{"key":"739_CR52","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41586-019-1817-8","volume":"577","author":"PA Darrah","year":"2020","unstructured":"Darrah, P. A. et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature 577, 95\u2013102 (2020).","journal-title":"Nature"},{"key":"739_CR53","doi-asserted-by":"crossref","first-page":"e1001965","DOI":"10.1371\/journal.pmed.1001965","volume":"13","author":"C Lienhardt","year":"2016","unstructured":"Lienhardt, C. et al. Translational research for tuberculosis elimination: Priorities, challenges, and actions. PLos Med. 13, e1001965 (2016).","journal-title":"PLos Med."},{"key":"739_CR54","doi-asserted-by":"crossref","first-page":"16076","DOI":"10.1128\/CMR.00100-19","volume":"33","author":"SB Sable","year":"2019","unstructured":"Sable, S. B., Posey, J. E. & Scriba, T. J. Tuberculosis vaccine development: Progress in clinical evaluation. Clin. Microbiol. Rev. 33, 16076\u201330 (2019).","journal-title":"Clin. Microbiol. Rev."},{"key":"739_CR55","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","volume":"379","author":"O Van Der Meeren","year":"2018","unstructured":"Van Der Meeren, O. et al. Phase 2b Controlled Trial of M72\/AS01 EVaccine to Prevent Tuberculosis. N. Engl. J. Med. 379, 1621\u20131634 (2018).","journal-title":"N. Engl. J. Med."},{"key":"739_CR56","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1714021","volume":"379","author":"E Nemes","year":"2018","unstructured":"Nemes, E. et al. Prevention of M. tuberculosisInfection with H4:IC31 Vaccine or BCG Revaccination. N. Engl. J. Med. 379, 138\u2013149 (2018).","journal-title":"N. Engl. J. Med."},{"key":"739_CR57","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.tube.2016.05.011","volume":"99","author":"LK Schrager","year":"2016","unstructured":"Schrager, L. K., Izzo, A. & Velmurugan, K. Immunopathogenesis of tuberculosis and novel mechanisms of vaccine activity. Tuberculosis 99, S3\u20137 (2016).","journal-title":"Tuberculosis"},{"key":"739_CR58","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1073\/pnas.1112648109","volume":"109","author":"JJ Moon","year":"2012","unstructured":"Moon, J. J. et al. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc. Natl Acad. Sci. USA 109, 1080\u20131085 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"739_CR59","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1016\/j.biomaterials.2012.03.041","volume":"33","author":"SL Demento","year":"2012","unstructured":"Demento, S. L. et al. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials 33, 4957\u20134964 (2012).","journal-title":"Biomaterials"},{"key":"739_CR60","doi-asserted-by":"crossref","first-page":"148rv9","DOI":"10.1126\/scitranslmed.3003763","volume":"4","author":"MA Swartz","year":"2012","unstructured":"Swartz, M. A., Hirosue, S. & Hubbell, J. A. Engineering approaches to immunotherapy. Sci. Transl. Med. 4, 148rv9\u2013148rv9 (2012).","journal-title":"Sci. Transl. Med."},{"key":"739_CR61","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1016\/j.vaccine.2010.09.077","volume":"28","author":"S Hirosue","year":"2010","unstructured":"Hirosue, S., Kourtis, I. C., van der Vlies, A. J., Hubbell, J. A. & Swartz, M. A. Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation. Vaccine 28, 7897\u20137906 (2010).","journal-title":"Vaccine"},{"key":"739_CR62","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/nbt1332","volume":"25","author":"ST Reddy","year":"2007","unstructured":"Reddy, S. T. et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 25, 1159\u20131164 (2007).","journal-title":"Nat. Biotechnol."},{"key":"739_CR63","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.addr.2011.05.016","volume":"63","author":"LM Kaminskas","year":"2011","unstructured":"Kaminskas, L. M. & Porter, C. J. H. Targeting the lymphatics using dendritic polymers (dendrimers). Adv. Drug Deliv. Rev. 63, 890\u2013900 (2011).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"739_CR64","doi-asserted-by":"crossref","first-page":"e61646","DOI":"10.1371\/journal.pone.0061646","volume":"8","author":"IC Kourtis","year":"2013","unstructured":"Kourtis, I. C. et al. Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. PLoS ONE 8, e61646 (2013).","journal-title":"PLoS ONE"},{"key":"739_CR65","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2004.11.013","volume":"22","author":"M Sixt","year":"2005","unstructured":"Sixt, M. et al. The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity 22, 19\u201329 (2005).","journal-title":"Immunity"},{"key":"739_CR66","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1021\/acsbiomaterials.6b00438","volume":"3","author":"NA Rohner","year":"2017","unstructured":"Rohner, N. A. & Thomas, S. N. Flexible macromolecule versus rigid particle retention in the injected skin and accumulation in draining lymph nodes are differentially influenced by hydrodynamic size. ACS Biomater. Sci. Eng. 3, 153\u2013159 (2017).","journal-title":"ACS Biomater. Sci. Eng."},{"key":"739_CR67","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.immuni.2007.02.011","volume":"26","author":"KA Pape","year":"2007","unstructured":"Pape, K. A., Catron, D. M., Itano, A. A. & Jenkins, M. K. The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles. Immunity 26, 491\u2013502 (2007).","journal-title":"Immunity"},{"key":"739_CR68","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jconrel.2010.08.012","volume":"147","author":"D Mohanan","year":"2010","unstructured":"Mohanan, D. et al. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. J. Control. Release 147, 342\u2013349 (2010).","journal-title":"J. Control. Release"},{"key":"739_CR69","doi-asserted-by":"crossref","first-page":"15745","DOI":"10.1073\/pnas.1105200108","volume":"108","author":"CM Jewell","year":"2011","unstructured":"Jewell, C. M., L\u00f3pez, S. C. B. & Irvine, D. J. In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles. Proc. Natl Acad. Sci. USA 108, 15745\u201315750 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"739_CR70","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.addr.2008.09.012","volume":"61","author":"SK Lai","year":"2009","unstructured":"Lai, S. K., Wang, Y. Y., Wirtz, D. & Hanes, J. Micro- and macrorheology of mucus. Adv. Drug Deliv. Rev. 61, 86\u2013100 (2009).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"739_CR71","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","volume":"61","author":"SK Lai","year":"2009","unstructured":"Lai, S. K., Wang, Y. Y. & Hanes, J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 61, 158\u2013171 (2009).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"739_CR72","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1073\/pnas.0911748107","volume":"107","author":"SK Lai","year":"2010","unstructured":"Lai, S. K., Wang, Y. Y., Hida, K., Cone, R. & Hanes, J. Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proc. Natl Acad. Sci. USA 107, 598\u2013603 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"739_CR73","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1016\/j.biomaterials.2013.01.064","volume":"34","author":"BS Schuster","year":"2013","unstructured":"Schuster, B. S., Suk, J. S., Woodworth, G. F. & Hanes, J. Nanoparticle diffusion in respiratory mucus from humans without lung disease. Biomaterials 34, 3439\u20133446 (2013).","journal-title":"Biomaterials"},{"key":"739_CR74","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ijbiomac.2017.10.101","volume":"110","author":"B Singh","year":"2018","unstructured":"Singh, B. et al. Chitosan-based particulate systems for the delivery of mucosal vaccines against infectious diseases. Int. J. Biol. Macromol. 110, 54\u201364 (2018).","journal-title":"Int. J. Biol. Macromol."},{"key":"739_CR75","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.vaccine.2003.09.044","volume":"22","author":"M Bivas-Benita","year":"2004","unstructured":"Bivas-Benita, M. et al. Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine 22, 1609\u20131615 (2004).","journal-title":"Vaccine"},{"key":"739_CR76","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1073\/pnas.0600997103","volume":"103","author":"JA Champion","year":"2006","unstructured":"Champion, J. A. & Mitragotri, S. Role of target geometry in phagocytosis. Proc. Natl Acad. Sci. USA 103, 4930\u20134934 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"739_CR77","first-page":"799","volume":"7","author":"SS Yu","year":"2012","unstructured":"Yu, S. S. et al. Size-and charge-dependent non-specific uptake of PEGylated nanoparticles by macrophages. IJN 7, 799\u2013813 (2012).","journal-title":"IJN"},{"key":"739_CR78","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.2147\/IJN.S36111","volume":"7","author":"E Fr\u00f6hlich","year":"2012","unstructured":"Fr\u00f6hlich, E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. IJN 7, 5577\u20135591 (2012).","journal-title":"IJN"},{"key":"739_CR79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymeth.2006.05.016","volume":"40","author":"SD Xiang","year":"2006","unstructured":"Xiang, S. D. et al. Pathogen recognition and development of particulate vaccines: Does size matter? Methods 40, 1\u20139 (2006).","journal-title":"Methods"},{"key":"739_CR80","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jconrel.2015.09.063","volume":"219","author":"J Leleux","year":"2015","unstructured":"Leleux, J., Atalis, A. & Roy, K. Engineering immunity: Modulating dendritic cell subsets and lymph node response to direct immune-polarization and vaccine efficacy. J. Control. Release 219, 610\u2013621 (2015).","journal-title":"J. Control. Release"},{"key":"739_CR81","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nri723","volume":"2","author":"CG Figdor","year":"2002","unstructured":"Figdor, C. G., van Kooyk, Y. & Adema, G. J. C-type lectin receptors on dendritic cells and langerhans cells. Nat. Rev. Immunol. 2, 77\u201384 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"739_CR82","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1126\/science.aat9120","volume":"363","author":"T Tokatlian","year":"2018","unstructured":"Tokatlian, T. et al. Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers. Science 363, 649\u2013654 (2018).","journal-title":"Science"},{"key":"739_CR83","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1073\/pnas.0511315103","volume":"103","author":"YM Kim","year":"2006","unstructured":"Kim, Y. M. et al. Monovalent ligation of the B cell receptor induces receptor activation but fails to promote antigen presentation. Proc. Natl Acad. Sci. USA 103, 3327\u20133332 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"739_CR84","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1016\/j.vaccine.2011.05.061","volume":"29","author":"D Smirnov","year":"2011","unstructured":"Smirnov, D., Schmidt, J. J., Capecchi, J. T. & Wightman, P. D. Vaccine adjuvant activity of 3M-052: An imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine 29, 5434\u20135442 (2011).","journal-title":"Vaccine"},{"key":"739_CR85","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.vaccine.2014.02.027","volume":"32","author":"PO Ilyinskii","year":"2014","unstructured":"Ilyinskii, P. O. et al. Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release. Vaccine 32, 2882\u20132895 (2014).","journal-title":"Vaccine"},{"key":"739_CR86","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1172\/JCI79915","volume":"125","author":"MC Hanson","year":"2015","unstructured":"Hanson, M. C. et al. Nanoparticulate STING agonists are potent lymph node\u2013targeted vaccine adjuvants. J. Clin. Invest. 125, 2532\u20132546 (2015).","journal-title":"J. Clin. Invest."},{"key":"739_CR87","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/0161-5890(93)90028-A","volume":"30","author":"M Friede","year":"1993","unstructured":"Friede, M., Muller, S., Briand, J.-P., Van Regenmortel, M. H. V. & Schuber, F. Induction of immune response against a short synthetic peptide antigen coupled to small neutral liposomes containing monophosphoryl lipid a. Mol. Immun. 30, 539\u2013547 (1993).","journal-title":"Mol. Immun."},{"key":"739_CR88","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s41565-018-0271-3","volume":"13","author":"WC Huang","year":"2018","unstructured":"Huang, W. C. et al. A malaria vaccine adjuvant based on recombinant antigen binding to liposomes. Nat. Nanotechnol. 13, 1174\u20131181 (2018).","journal-title":"Nat. Nanotechnol."},{"key":"739_CR89","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0167-5699(96)10066-9","volume":"17","author":"MF Bachmann","year":"1996","unstructured":"Bachmann, M. F. & Zinkernagel, R. M. The Influence of virus structure on antibody responses and virus serotype formation. Immunol. Today 17, 553\u2013558 (1996).","journal-title":"Immunol. Today"},{"key":"739_CR90","doi-asserted-by":"crossref","first-page":"e1004254","DOI":"10.1371\/journal.ppat.1004254","volume":"10","author":"j schiller","year":"2014","unstructured":"schiller, j & chackerian, b why hiv virions have low numbers of envelope spikes: Implications for vaccine development. PLoS Pathog. 10, e1004254 (2014).","journal-title":"PLoS Pathog."},{"key":"739_CR91","doi-asserted-by":"crossref","first-page":"8776","DOI":"10.1016\/j.biomaterials.2013.07.063","volume":"34","author":"J Chen","year":"2013","unstructured":"Chen, J. et al. The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation. Biomaterials 34, 8776\u20138785 (2013).","journal-title":"Biomaterials"},{"key":"739_CR92","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.vaccine.2013.11.047","volume":"32","author":"CB Chesson","year":"2014","unstructured":"Chesson, C. B. et al. Antigenic peptide nanofibers elicit adjuvant-free CD8+ T cell responses. Vaccine 32, 1174\u20131180 (2014).","journal-title":"Vaccine"},{"key":"739_CR93","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1002\/adma.201200209","volume":"24","author":"M Black","year":"2012","unstructured":"Black, M. et al. Self-assembled peptide amphiphile micelles containing a cytotoxic T-cell epitope promote a protective immune response in vivo. Adv. Mater. 24, 3845\u20133849 (2012).","journal-title":"Adv. Mater."},{"key":"739_CR94","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1021\/acsbiomaterials.6b00422","volume":"3","author":"JC Barrett","year":"2016","unstructured":"Barrett, J. C. et al. Modular Peptide Amphiphile Micelles Improving an Antibody-Mediated Immune Response to Group A Streptococcus. ACS Biomater. Sci. Eng. 3, 144\u2013152 (2016).","journal-title":"ACS Biomater. Sci. Eng."},{"key":"739_CR95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2017.09.031","volume":"149","author":"C Mora-Solano","year":"2017","unstructured":"Mora-Solano, C. et al. Active immunotherapy for TNF-mediated inflammation using self-assembled peptide nanofibers. Biomaterials 149, 1\u201311 (2017).","journal-title":"Biomaterials"},{"key":"739_CR96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/126794","volume":"2011","author":"S Babapoor","year":"2011","unstructured":"Babapoor, S. et al. A Novel vaccine using nanoparticle platform to present immunogenic M2e against avian influenza infection. Influenza Res. Trea. 2011, 1\u201312 (2011).","journal-title":"Influenza Res. Trea."},{"key":"739_CR97","doi-asserted-by":"crossref","first-page":"e48304","DOI":"10.1371\/journal.pone.0048304","volume":"7","author":"SA Kaba","year":"2012","unstructured":"Kaba, S. A. et al. ProtectiveaAntibody and CD8+ T-cell responses to the plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine. PLoS ONE 7, e48304 (2012).","journal-title":"PLoS ONE"},{"key":"739_CR98","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1002\/anie.201002221","volume":"49","author":"M Skwarczynski","year":"2010","unstructured":"Skwarczynski, M. et al. Polyacrylate dendrimer nanoparticles: A self-adjuvanting vaccine delivery system. Angew. Chem. Int. Ed. 49, 5742\u20135745 (2010).","journal-title":"Angew. Chem. Int. Ed."},{"key":"739_CR99","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1073\/pnas.73.10.3671","volume":"73","author":"HM Dintzis","year":"1976","unstructured":"Dintzis, H. M., Dintzis, R. Z. & Vogelstein, B. Molecular determinants of immunogenicity: The immunon model of immune response. Proc. Natl Acad. Sci. USA 73, 3671\u20133675 (1976).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"739_CR100","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1073\/pnas.79.3.884","volume":"79","author":"RZ Dintzis","year":"1982","unstructured":"Dintzis, R. Z., Vogelstein, B. & Dintzis, H. M. Specific cellular stimulation in the primary immune response: Experimental test of a quantized model. Proc. Natl Acad. Sci. USA 79, 884\u2013888 (1982).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"739_CR101","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.4049\/jimmunol.143.4.1239","volume":"143","author":"RZ Dintzis","year":"1989","unstructured":"Dintzis, R. Z., Okajima, M., Middleton, M. H., Greene, G. & Dintzis, H. M. The immunogenicity of soluble haptenated polymers is determined by molecular mass and hapten valence. J. Immunol. 143, 1239\u20131244 (1989).","journal-title":"J. Immunol."},{"key":"739_CR102","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1021\/nn204530r","volume":"6","author":"JS Rudra","year":"2012","unstructured":"Rudra, J. S. et al. Modulating adaptive immune responses to peptide self-assemblies. ACS Nano 6, 1557\u20131564 (2012).","journal-title":"ACS Nano"},{"key":"739_CR103","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/emboj\/19.4.513","volume":"19","author":"FD Batista","year":"2000","unstructured":"Batista, F. D. & Neuberger, M. S. B cells extract and present immobilized antigen: implications for affinity discrimination. EMBO J. 19, 513\u2013520 (2000).","journal-title":"EMBO J."},{"key":"739_CR104","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.4049\/jimmunol.169.11.6120","volume":"169","author":"B Chackerian","year":"2002","unstructured":"Chackerian, B., Lenz, P., Lowy, D. R. & Schiller, J. T. Determinants of Autoantibody Induction by Conjugated Papillomavirus Virus-Like Particles. J. Immunol. 169, 6120\u20136126 (2002).","journal-title":"J. Immunol."},{"key":"739_CR105","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1021\/cb600489g","volume":"2","author":"EB Puffer","year":"2007","unstructured":"Puffer, E. B., Pontrello, J. K., Hollenbeck, J. J., Kink, J. A. & Kiessling, L. L. Activating B cell signaling with defined multivalent ligands. ACS Chem. Biol. 2, 252\u2013262 (2007).","journal-title":"ACS Chem. Biol."},{"key":"739_CR106","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1021\/acschembio.5b00239","volume":"10","author":"NR Bennett","year":"2015","unstructured":"Bennett, N. R., Zwick, D. B., Courtney, A. H. & Kiessling, L. L. Multivalent antigens for promoting B and T cell activation. ACS Chem. Biol. 10, 1817\u20131824 (2015).","journal-title":"ACS Chem. Biol."},{"key":"739_CR107","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/adhm.201400137","volume":"3","author":"RR Pompano","year":"2014","unstructured":"Pompano, R. R. et al. Titrating T-cell epitopes within self-assembled vaccines optimizes CD4+ helper T cell and antibody outputs. Adv. Healthc. Mater. 3, 1898\u20131908 (2014).","journal-title":"Adv. Healthc. Mater."},{"key":"739_CR108","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.immuni.2018.08.012","volume":"49","author":"S Hong","year":"2018","unstructured":"Hong, S. et al. B cells are the dominant antigen-presenting cells that activate naive CD4+ T cells upon immunization with a virus-derived nanoparticle antigen. Immunity 49, 695\u2013708e4 (2018).","journal-title":"Immunity"},{"key":"739_CR109","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1021\/bc5002246","volume":"25","author":"S Pejawar-Gaddy","year":"2014","unstructured":"Pejawar-Gaddy, S., Kovacs, J. M., Barouch, D. H., Chen, B. & Irvine, D. J. Design of Lipid Nanocapsule Delivery vehicles for multivalent display of recombinant Env trimers in HIV vaccination. Bioconjugate Chem. 25, 1470\u20131478 (2014).","journal-title":"Bioconjugate Chem."},{"key":"739_CR110","first-page":"1986","volume":"15","author":"J Ingale","year":"2016","unstructured":"Ingale, J. et al. High-density array of well-ordered HIV-1 spikes on synthetic liposomal nanoparticles efficiently activate B cells. CellReports 15, 1986\u20131999 (2016).","journal-title":"CellReports"},{"key":"739_CR111","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","volume":"176","author":"J Marcandalli","year":"2019","unstructured":"Marcandalli, J. et al. Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. Cell 176, 1420\u20131431e17 (2019).","journal-title":"Cell"},{"key":"739_CR112","volume":"10","author":"PJM Brouwer","year":"2019","unstructured":"Brouwer, P. J. M. et al. Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. Nat. Commun. 10, 4247 (2019).","journal-title":"Nat. Commun."},{"key":"739_CR113","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","volume":"162","author":"M Kanekiyo","year":"2015","unstructured":"Kanekiyo, M. et al. Rational design of an Epstein-Barr Virus vaccine targeting the receptor-binding site. Cell 162, 1090\u20131100 (2015).","journal-title":"Cell"},{"key":"739_CR114","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.immuni.2017.05.007","volume":"46","author":"M Pauthner","year":"2017","unstructured":"Pauthner, M. et al. Elicitation of robust tier 2 neutralizing antibody responses in nonhuman primates by HIV envelope trimer immunization using optimized approaches. Immunity 46, 1073\u20131088e6 (2017).","journal-title":"Immunity"},{"key":"739_CR115","volume":"8","author":"DW Kulp","year":"2017","unstructured":"Kulp, D. W. et al. Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding. Nat. Commun. 8, 1655 (2017).","journal-title":"Nat. Commun."},{"key":"739_CR116","doi-asserted-by":"crossref","first-page":"7832","DOI":"10.1021\/acs.nanolett.8b03601","volume":"18","author":"JD Bazzill","year":"2018","unstructured":"Bazzill, J. D. et al. Interrogation of antigen display on individual vaccine nanoparticles for achieving neutralizing antibody responses against hepatitis C virus. Nano Lett. 18, 7832\u20137838 (2018).","journal-title":"Nano Lett."},{"key":"739_CR117","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.immuni.2017.04.021","volume":"46","author":"P Martinez-Murillo","year":"2017","unstructured":"Martinez-Murillo, P. et al. Particulate array of well-ordered HIV clade C Env trimers elicits neutralizing antibodies that display a unique V2 cap approach. Immunity 46, 804\u2013817e7 (2017).","journal-title":"Immunity"},{"key":"739_CR118","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature12202","volume":"499","author":"M Kanekiyo","year":"2013","unstructured":"Kanekiyo, M. et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499, 102\u2013106 (2013).","journal-title":"Nature"},{"key":"739_CR119","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/infdis\/171.6.1576","volume":"171","author":"DM Gordon","year":"1995","unstructured":"Gordon, D. M. et al. Safety, immunogenicity, and efficacy of a recombinantly produced plasmodium falciparum circumsporozite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171, 1576\u20131585 (1995).","journal-title":"J. Infect. Dis."},{"key":"739_CR120","first-page":"711","volume":"340","author":"T Nieusma","year":"2013","unstructured":"Nieusma, T. et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 340, 711\u2013716 (2013).","journal-title":"Science"},{"key":"739_CR121","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.nbt.2014.12.006","volume":"32","author":"D He","year":"2015","unstructured":"He, D. & Marles-Wright, J. Ferritin family proteins and their use in bionanotechnology. N. Biotechnol. 32, 651\u2013657 (2015).","journal-title":"N. Biotechnol."},{"key":"739_CR122","doi-asserted-by":"crossref","DOI":"10.1186\/s12977-015-0210-4","volume":"12","author":"K Sliepen","year":"2015","unstructured":"Sliepen, K. et al. Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity. Retrovirology 12, 82 (2015).","journal-title":"Retrovirology"},{"key":"739_CR123","doi-asserted-by":"crossref","first-page":"eaay7199","DOI":"10.1126\/science.aay7199","volume":"366","author":"KO Saunders","year":"2019","unstructured":"Saunders, K. O. et al. Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. Science 366, eaay7199\u201319 (2019).","journal-title":"Science"},{"key":"739_CR124","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1128\/IAI.01369-07","volume":"76","author":"SA Ogun","year":"2008","unstructured":"Ogun, S. A., Dumon-Seignovert, L., Marchand, J. B., Holder, A. A. & Hill, F. The oligomerization domain of C4-binding protein (C4bp) acts as an adjuvant, and the fusion protein comprised of the 19-kilodalton merozoite surface protein 1 fused with the murine C4bp domain protects mice against malaria. Infect. Immun. 76, 3817\u20133823 (2008).","journal-title":"Infect. Immun."},{"key":"739_CR125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0001-8","volume":"6","author":"Y Li","year":"2016","unstructured":"Li, Y. et al. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology. Sci. Rep. 6, 1\u201313 (2016).","journal-title":"Sci. Rep."},{"key":"739_CR126","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.3389\/fimmu.2018.02780","volume":"9","author":"F Brod","year":"2018","unstructured":"Brod, F. et al. Combination of RTS, S and Pfs25-IMX313 induces a functional antibody response against malaria infection and transmission in mice. Front. Immunol. 9, e474 (2018).","journal-title":"Front. Immunol."},{"key":"739_CR127","doi-asserted-by":"crossref","first-page":"e33555","DOI":"10.1371\/journal.pone.0033555","volume":"7","author":"AJ Spencer","year":"2012","unstructured":"Spencer, A. J. et al. Fusion of the Mycobacterium tuberculosis Antigen 85A to an Oligomerization Domain Enhances Its Immunogenicity in Both Mice and Non-Human Primates. PLoS ONE 7, e33555 (2012).","journal-title":"PLoS ONE"},{"key":"739_CR128","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.vaccine.2016.01.062","volume":"34","author":"A Minhinnick","year":"2016","unstructured":"Minhinnick, A. et al. A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults. Vaccine 34, 1412\u20131421 (2016).","journal-title":"Vaccine"},{"key":"739_CR129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.00001","volume":"9","author":"Y Gao","year":"2018","unstructured":"Gao, Y., Wijewardhana, C. & Mann, J. F. S. Virus-like particle, liposome, and polymeric particle-based vaccines against HIV-1. Front. Immunol. 9, 1\u201318 (2018).","journal-title":"Front. Immunol."},{"key":"739_CR130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","volume":"34","author":"MO Mohsen","year":"2017","unstructured":"Mohsen, M. O., Zha, L., Cabral-Miranda, G. & Bachmann, M. F. Major findings and recent advances in virus\u2013like particle (VLP)-based vaccines. Semin. Immunol. 34, 123\u2013132 (2017).","journal-title":"Semin. Immunol."},{"key":"739_CR131","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12033-012-9598-4","volume":"53","author":"A Zeltins","year":"2012","unstructured":"Zeltins, A. Construction and characterization of virus-like particles: A review. Mol. Biotechnol. 53, 92\u2013107 (2012).","journal-title":"Mol. Biotechnol."},{"key":"739_CR132","first-page":"1","volume":"91","author":"MB Zwick","year":"2017","unstructured":"Zwick, M. B. et al. Dense array of spikes on HIV-1 Virion particles. J. Virol. 91, 1\u201319 (2017).","journal-title":"J. Virol."},{"key":"739_CR133","doi-asserted-by":"crossref","first-page":"e0177863","DOI":"10.1371\/journal.pone.0177863","volume":"12","author":"NP McCurley","year":"2017","unstructured":"McCurley, N. P. et al. HIV transmitted\/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site. PLoS ONE 12, e0177863 (2017).","journal-title":"PLoS ONE"},{"key":"739_CR134","doi-asserted-by":"crossref","first-page":"7268","DOI":"10.4049\/jimmunol.0901957","volume":"183","author":"SA Kaba","year":"2009","unstructured":"Kaba, S. A. et al. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. J. Immunol. 183, 7268\u20137277 (2009).","journal-title":"J. Immunol."},{"key":"739_CR135","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.vaccine.2013.11.069","volume":"32","author":"L Zhao","year":"2014","unstructured":"Zhao, L. et al. Nanoparticle vaccines. Vaccine 32, 327\u2013337 (2014).","journal-title":"Vaccine"},{"key":"739_CR136","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.addr.2007.05.017","volume":"60","author":"LJ Peek","year":"2008","unstructured":"Peek, L. J., Middaugh, C. R. & Berkland, C. Nanotechnology in vaccine delivery. Adv. Drug Deliv. Rev. 60, 915\u2013928 (2008).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"739_CR137","first-page":"S21","volume":"10","author":"JL Cleland","year":"1994","unstructured":"Cleland, J. L. et al. Development of a single-shot subunit vaccine for HIV-1. AIDS Res. Hum. Retrovir. 10, S21\u20136 (1994).","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"739_CR138","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.imlet.2017.05.002","volume":"187","author":"H Rostami","year":"2017","unstructured":"Rostami, H., Ebtekar, M., Ardestani, M. S., Yazdi, M. H. & Mahdavi, M. Co-utilization of a TLR5 agonist and nano-formulation of HIV-1 vaccine candidate leads to increased vaccine immunogenicity and decreased immunogenic dose: A preliminary study. Immunol. Lett. 187, 19\u201326 (2017).","journal-title":"Immunol. Lett."},{"key":"739_CR139","doi-asserted-by":"crossref","unstructured":"Kasturi, S. P. et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470, 543\u2013547","DOI":"10.1038\/nature09737"},{"key":"739_CR140","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1021\/acs.molpharmaceut.7b00586","volume":"14","author":"BA Bailey","year":"2017","unstructured":"Bailey, B. A. et al. Self-encapsulating Poly(lactic- co-glycolic acid) (PLGA) microspheres for intranasal vaccine delivery. Mol. Pharmaceutics 14, 3228\u20133237 (2017).","journal-title":"Mol. Pharmaceutics"},{"key":"739_CR141","first-page":"1601418","volume":"6","author":"BA Bailey","year":"2017","unstructured":"Bailey, B. A., Ochyl, L. J., Schwendeman, S. P. & Moon, J. J. Toward a single-dose vaccination strategy with self-encapsulating PLGA microspheres. Adv. Funct. Mater. 6, 1601418 (2017).","journal-title":"Adv. Funct. Mater."},{"key":"739_CR142","doi-asserted-by":"crossref","first-page":"9038","DOI":"10.1016\/j.vaccine.2011.09.031","volume":"29","author":"MS Cherif","year":"2011","unstructured":"Cherif, M. S. et al. Immunogenicity of novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine using different routes of administration. Vaccine 29, 9038\u20139050 (2011).","journal-title":"Vaccine"},{"key":"739_CR143","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0168-3659(01)00407-2","volume":"75","author":"Z Cui","year":"2001","unstructured":"Cui, Z. & Mumper, R. J. Chitosan-based nanoparticles for topical genetic immunization. J. Control. Release 75, 409\u2013419 (2001).","journal-title":"J. Control. Release"},{"key":"739_CR144","doi-asserted-by":"crossref","first-page":"e61135","DOI":"10.1371\/journal.pone.0061135","volume":"8","author":"G Feng","year":"2013","unstructured":"Feng, G. et al. Enhanced immune response and protective effects of nano-chitosan-based DNA vaccine encoding T Cell epitopes of Esat-6 and FL against Mycobacterium Tuberculosis infection. PLoS ONE 8, e61135 (2013).","journal-title":"PLoS ONE"},{"key":"739_CR145","doi-asserted-by":"crossref","first-page":"E4133","DOI":"10.1073\/pnas.1600299113","volume":"113","author":"JS Chahal","year":"2016","unstructured":"Chahal, J. S. et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc. Natl Acad. Sci. USA 113, E4133\u2013E4142 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"739_CR146","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1016\/j.biomaterials.2009.05.078","volume":"30","author":"SF Chong","year":"2009","unstructured":"Chong, S. F. et al. A paradigm for peptide vaccine delivery using viral epitopes encapsulated in degradable polymer hydrogel capsules. Biomaterials 30, 5178\u20135186 (2009).","journal-title":"Biomaterials"},{"key":"739_CR147","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nmat3550","volume":"12","author":"PC DeMuth","year":"2013","unstructured":"DeMuth, P. C. et al. Polymer multilayer tattooing for enhanced DNA vaccination. Nat. Mater. 12, 367\u2013375 (2013).","journal-title":"Nat. Mater."},{"key":"739_CR148","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-34853-2","volume":"8","author":"T Tokatlian","year":"2018","unstructured":"Tokatlian, T. et al. Enhancing humoral responses against HIV envelope trimers via nanoparticle delivery with stabilized synthetic liposomes. Sci. Rep. 8, 16527 (2018).","journal-title":"Sci. Rep."},{"key":"739_CR149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcimb.2013.00013","volume":"3","author":"AE Gregory","year":"2013","unstructured":"Gregory, A. E., Titball, R. & Williamson, D. Vaccine delivery using nanoparticles. Front. Cell. Infect. Microbiol. 3, 1\u201313 (2013).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"739_CR150","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1016\/j.vaccine.2015.08.025","volume":"33","author":"R Kumar","year":"2015","unstructured":"Kumar, R. et al. Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles. Vaccine 33, 5064\u20135071 (2015).","journal-title":"Vaccine"},{"key":"739_CR151","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.nano.2017.11.009","volume":"14","author":"N Climent","year":"2017","unstructured":"Climent, N. et al. Loading dendritic cells with gold nanoparticles (GNPs) bearing HIV-peptides and mannosides enhance HIV-specific T cell responses. Nanomedicine 14, 339\u2013351 (2017).","journal-title":"Nanomedicine"},{"key":"739_CR152","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.nano.2012.02.015","volume":"8","author":"F Yu","year":"2012","unstructured":"Yu, F. et al. Nanoparticle-based adjuvant for enhanced protective efficacy of DNA vaccine Ag85A-ESAT-6-IL-21 against Mycobacterium tuberculosis infection. Nanomedicine 8, 1337\u20131344 (2012).","journal-title":"Nanomedicine"},{"key":"739_CR153","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1002\/adma.201300583","volume":"25","author":"L Xu","year":"2013","unstructured":"Xu, L. et al. Morphologically virus-like fullerenol nanoparticles act as the dual-functional nanoadjuvant for HIV-1 vaccine. Adv. Mater. 25, 5928\u20135936 (2013).","journal-title":"Adv. Mater."},{"key":"739_CR154","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.actbio.2015.11.019","volume":"30","author":"T Sun","year":"2016","unstructured":"Sun, T. et al. Thermal stability of self-assembled peptide vaccine materials. Acta Biomaterialia 30, 62\u201371 (2016).","journal-title":"Acta Biomaterialia"},{"key":"739_CR155","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-31089-y","volume":"8","author":"CB Chesson","year":"2018","unstructured":"Chesson, C. B. et al. Nanoscale peptide self-assemblies boost BCG-primed cellular immunity against mycobacterium tuberculosis. Sci. Rep. 8, 12519 (2018).","journal-title":"Sci. Rep."},{"key":"739_CR156","doi-asserted-by":"crossref","first-page":"6476","DOI":"10.1016\/j.biomaterials.2012.05.041","volume":"33","author":"JS Rudra","year":"2012","unstructured":"Rudra, J. S. et al. Self-assembled peptide nanofibers raising durable antibody responses against a malaria epitope. Biomaterials 33, 6476\u20136484 (2012).","journal-title":"Biomaterials"},{"key":"739_CR157","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1073\/pnas.0912124107","volume":"107","author":"JS Rudra","year":"2010","unstructured":"Rudra, J. S., Tian, Y. F., Jung, J. P. & Collier, J. H. A self-assembling peptide acting as an immune adjuvant. Proc. Natl Acad. Sci. USA 107, 622\u2013627 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"739_CR158","doi-asserted-by":"crossref","unstructured":"Solano, C. M., Wen, Y., Han, H. & Collier, J. H. in Peptide Self-Assembly: Methods and Protocols (eds. Nilsson, B. L. & Doran, T. M.) 233\u2013248 (Springer New York, 2018).","DOI":"10.1007\/978-1-4939-7811-3_14"},{"key":"739_CR159","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jconrel.2018.04.031","volume":"282","author":"Y Si","year":"2018","unstructured":"Si, Y., Wen, Y., Kelly, S. H., Chong, A. S. & Collier, J. H. Intranasal delivery of adjuvant-free peptide nanofibers elicits resident CD8+ T cell responses. J. Control. Release 282, 120\u2013130 (2018).","journal-title":"J. Control. Release"},{"key":"739_CR160","doi-asserted-by":"crossref","first-page":"9274","DOI":"10.1021\/acsnano.6b03409","volume":"10","author":"Y Wen","year":"2016","unstructured":"Wen, Y., Waltman, A., Han, H. & Collier, J. H. Switching the immunogenicity of peptide assemblies using surface properties. ACS Nano 10, 9274\u20139286 (2016).","journal-title":"ACS Nano"},{"key":"739_CR161","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1021\/acsbiomaterials.7b00561","volume":"3","author":"Y Wu","year":"2017","unstructured":"Wu, Y. et al. A Supramolecular vaccine platform based on \u03b1-helical peptide nanofibers. ACS Biomater. Sci. Eng. 3, 3128\u20133132 (2017).","journal-title":"ACS Biomater. Sci. Eng."},{"key":"739_CR162","doi-asserted-by":"crossref","unstructured":"Hudalla, G. A. et al. A Self-adjuvanting supramolecular vaccine carrying a folded protein antigen. 2, 1114\u20131119 (2014).","DOI":"10.1002\/adhm.201200435"},{"key":"739_CR163","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nmat3998","volume":"13","author":"GA Hudalla","year":"2014","unstructured":"Hudalla, G. A. et al. Gradated assembly of multiple proteins into supramolecular nanomaterials. Nat. Mater. 13, 829\u2013836 (2014).","journal-title":"Nat. Mater."},{"key":"739_CR164","doi-asserted-by":"crossref","first-page":"e48304","DOI":"10.1371\/journal.pone.0048304","volume":"7","author":"SA Kaba","year":"2012","unstructured":"Kaba, S. A. et al. Protective Antibody and CD8+ T-Cell responses to the plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine. PLoS ONE 7, e48304\u201311 (2012).","journal-title":"PLoS ONE"},{"key":"739_CR165","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nmat2960","volume":"10","author":"JJ Moon","year":"2011","unstructured":"Moon, J. J. et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat. Mater. 10, 243\u2013251 (2011).","journal-title":"Nat. Mater."},{"key":"739_CR166","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/ni1494","volume":"8","author":"TG Phan","year":"2007","unstructured":"Phan, T. G., Grigorova, I., Okada, T. & Cyster, J. G. Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. Nat. Immunol. 8, 992\u20131000 (2007).","journal-title":"Nat. Immunol."},{"key":"739_CR167","doi-asserted-by":"crossref","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","volume":"88","author":"Q Yang","year":"2016","unstructured":"Yang, Q. et al. Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population. Anal. Chem. 88, 11804\u201311812 (2016).","journal-title":"Anal. Chem."},{"key":"739_CR168","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s11095-013-1067-7","volume":"30","author":"H Schellekens","year":"2013","unstructured":"Schellekens, H., Hennink, W. E. & Brinks, V. The immunogenicity of polyethylene glycol: Facts and fiction. Pharm. Res. 30, 1729\u20131734 (2013).","journal-title":"Pharm. Res."},{"key":"739_CR169","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2011.12.017","volume":"159","author":"Y Zhuang","year":"2012","unstructured":"Zhuang, Y. et al. PEGylated cationic liposomes robustly augment vaccine-induced immune responses: Role of lymphatic trafficking and biodistribution. J. Control. Release 159, 135\u2013142 (2012).","journal-title":"J. Control. Release"},{"key":"739_CR170","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1016\/j.vaccine.2015.08.025","volume":"33","author":"R Kumar","year":"2015","unstructured":"Kumar, R. et al. Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles. Vaccine 33, 5064\u20135071 (2015).","journal-title":"Vaccine"}],"container-title":["Nature Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41565-020-0739-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41565-020-0739-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41565-020-0739-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T21:56:36Z","timestamp":1696542996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41565-020-0739-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":170,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["739"],"URL":"https:\/\/doi.org\/10.1038\/s41565-020-0739-9","relation":{},"ISSN":["1748-3387","1748-3395"],"issn-type":[{"value":"1748-3387","type":"print"},{"value":"1748-3395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,17]]},"assertion":[{"value":"4 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.H.C., S.R.P., G.G.F. and C.N.F. are inventors on a patent application associated with the technology areas described.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}